journal cover

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group

The New England Journal of Medicine

Oct 9, 1997

Stephan R TarganPaul Rutgeerts

Download from

Publisher
PubMed

Abstract

Studies in animals and an open-label trial have suggested a role for antibodies to tumor necrosis factor alpha, specifically chimeric monoclonal antibody cA2, in the treatment of Crohn's disease. We conducted a 12-week multicenter, double-blind, placebo-controlled trial of cA2 in 108 pa...read more

Mentioned in this Paper

Monoclonal Antibodies
IIeocolitis
Necrosis
Tumor Necrosis Factor-alpha
Chimeric Proteins, Recombinant
Chimera Organism
Weighing Patient
Adverse Effects
Crohn's Disease Activity Index
Cancer Remission
1
324
Paper Details
References
  • References23
  • Citations1425
123
  • References23
  • Citations1425
12345...

Feeds With Similar Papers

General Medical Journal eTOCs

Discover the latest medical research in this collection of the top medical journals.

Inflammatory Bowel Disease

Inflammatory bowel diseases (IBD), Crohn’s disease and ulcerative colitis, arise due to chronic inflammation of the gastrointestinal tract. Here is the latest research.

NEJM eTOC

The New England Journal of Medicine (NEJM) is a medical journal published by the Massachusetts Medical Society. Discover the latest research from NEJM here.

Related Papers

The New England Journal of Medicine

Infliximab for the treatment of fistulas in patients with Crohn's disease(opens in new tab)

The New England Journal of MedicineMay 6, 1999
D H PresentS J van Deventer
© 2020 Meta ULC. All rights reserved

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group

The New England Journal of Medicine

Oct 9, 1997

Stephan R TarganPaul Rutgeerts

PMID: 9321530

DOI: 10.1056/nejm199710093371502

Abstract

Studies in animals and an open-label trial have suggested a role for antibodies to tumor necrosis factor alpha, specifically chimeric monoclonal antibody cA2, in the treatment of Crohn's disease. We conducted a 12-week multicenter, double-blind, placebo-controlled trial of cA2 in 108 pa...read more

Mentioned in this Paper

Monoclonal Antibodies
IIeocolitis
Necrosis
Tumor Necrosis Factor-alpha
Chimeric Proteins, Recombinant
Chimera Organism
Weighing Patient
Adverse Effects
Crohn's Disease Activity Index
Cancer Remission
1
324

Feeds With Similar Papers

General Medical Journal eTOCs

Discover the latest medical research in this collection of the top medical journals.

Inflammatory Bowel Disease

Inflammatory bowel diseases (IBD), Crohn’s disease and ulcerative colitis, arise due to chronic inflammation of the gastrointestinal tract. Here is the latest research.

Related Papers

The New England Journal of Medicine

Infliximab for the treatment of fistulas in patients with Crohn's disease(opens in new tab)

The New England Journal of MedicineMay 6, 1999
D H PresentS J van Deventer
Paper Details
References
  • References23
  • Citations1425
123
  • References23
  • Citations1425
12345...

Download from

Publisher
PubMed
/papers/a-short-term-study-of-chimeric-monoclonal/9321530